Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.33 |
| ▸ | SCN1A | P35498 | 3/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807690 | 1.00 | NR3C1 (0.37) | NR3C1PGRNR3C2HRH4SCN5A | |
| SCHEMBL27154529 | 1.00 | NR3C1 (0.37) | NR3C1PGRNR3C2HRH4SCN5A | |
| SCHEMBL31092623 | 0.96 | NR3C1 (0.38) | NR3C1PGRNR3C2HRH4SCN5A | |
| SCHEMBL27146021 | 0.96 | NR3C1 (0.38) | NR3C1PGRNR3C2HRH4SCN5A | |
| SCHEMBL30807621 | 0.96 | NR3C1 (0.38) | NR3C1PGRNR3C2HRH4SCN5A | |
| SCHEMBL27146019 | 0.96 | NR3C1 (0.38) | NR3C1PGRNR3C2HRH4SCN5A | |
| SCHEMBL31092589 | 0.91 | NR3C1 (0.40) | NR3C1PGRNR3C2SCN5ASCN1A | |
| SCHEMBL30807603 | 0.88 | NR3C1 (0.39) | NR3C1PGRNR3C2SCN5ASCN1A | |
| SCHEMBL27145036 | 0.88 | NR3C1 (0.39) | NR3C1PGRNR3C2SCN5ASCN1A | |
| SCHEMBL27145035 | 0.88 | NR3C1 (0.39) | NR3C1PGRNR3C2SCN5ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | NR3C1 2938/4885PGR 2060/4885NR3C2 3200/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | NR3C1 2654/4885PGR 1907/4885NR3C2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.